CN117813395A - 转录状态和蛋白质组织学的联合绘图 - Google Patents

转录状态和蛋白质组织学的联合绘图 Download PDF

Info

Publication number
CN117813395A
CN117813395A CN202280038532.7A CN202280038532A CN117813395A CN 117813395 A CN117813395 A CN 117813395A CN 202280038532 A CN202280038532 A CN 202280038532A CN 117813395 A CN117813395 A CN 117813395A
Authority
CN
China
Prior art keywords
cells
oligonucleotide probe
disease
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280038532.7A
Other languages
English (en)
Chinese (zh)
Inventor
王潇
H·曾
J·任
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Broad Institute
Original Assignee
Massachusetts Institute of Technology
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Broad Institute filed Critical Massachusetts Institute of Technology
Publication of CN117813395A publication Critical patent/CN117813395A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/125—Rolling circle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/162—Helper probe
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280038532.7A 2021-05-28 2022-05-27 转录状态和蛋白质组织学的联合绘图 Pending CN117813395A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194536P 2021-05-28 2021-05-28
US63/194,536 2021-05-28
PCT/US2022/031275 WO2022251586A1 (en) 2021-05-28 2022-05-27 Co-mapping transcriptional states and protein histology

Publications (1)

Publication Number Publication Date
CN117813395A true CN117813395A (zh) 2024-04-02

Family

ID=82321599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280038532.7A Pending CN117813395A (zh) 2021-05-28 2022-05-27 转录状态和蛋白质组织学的联合绘图

Country Status (9)

Country Link
US (1) US20240376530A1 (cg-RX-API-DMAC7.html)
EP (2) EP4347878B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024522350A (cg-RX-API-DMAC7.html)
KR (1) KR20240014486A (cg-RX-API-DMAC7.html)
CN (1) CN117813395A (cg-RX-API-DMAC7.html)
AU (1) AU2022281407A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219339A1 (cg-RX-API-DMAC7.html)
IL (1) IL308570A (cg-RX-API-DMAC7.html)
WO (1) WO2022251586A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119068988A (zh) * 2024-08-13 2024-12-03 北京国浩宇医疗科技有限公司 一种针对单细胞表达谱的智能化异常检测系统

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112243463B (zh) 2018-04-09 2024-12-13 小利兰·斯坦福大学托管委员会 原位基因测序方法
US12497651B2 (en) 2020-11-23 2025-12-16 Pleno, Inc. Encoded dual-probe endonuclease assays
EP4738279A3 (en) 2021-02-19 2026-05-13 The Broad Institute Inc. Multi-scale spatial transcriptomics analysis
EP4334471A1 (en) 2021-05-07 2024-03-13 The Broad Institute Inc. Spatiotemporally resolved transcriptomics at subcellular resolution
DE102022131444A1 (de) * 2022-11-28 2024-05-29 Carl Zeiss Microscopy Gmbh Verfahren zum Identifizieren von Analyten in einer Bildfolge
CN116189880A (zh) * 2023-01-21 2023-05-30 中国医学科学院北京协和医院 一种肺腺癌脑转移的预测指标及预测方法和应用
WO2025136916A1 (en) 2023-12-18 2025-06-26 The Board Institute, Inc. Thick tissue transcriptomics and translatomics
WO2025189030A1 (en) 2024-03-07 2025-09-12 Stellaromics, Inc. Methods and systems for volumetric imaging

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107863D0 (en) * 2011-05-11 2011-06-22 Olink Ab Method and product
US10138509B2 (en) * 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
CN108474022A (zh) * 2015-11-03 2018-08-31 哈佛学院董事及会员团体 用于包含三维核酸的基质容积成像的设备和方法
HK1254531A1 (zh) * 2015-12-02 2019-07-19 Clearlight Diagnostics Llc 用於癌症检测和监测肿瘤组织样品的制备和分析方法
JP6811843B2 (ja) * 2016-08-19 2021-01-13 アリゾナ・ボード・オブ・リジェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシィティ 個々の細胞から対合ｍＲＮＡを捕捉及びシーケンスするためのボウタイ状バーコードの油乳化剤の大量合成
US20180208975A1 (en) * 2017-01-20 2018-07-26 Merck Sharp & Dohme Corp. Assay for simultaneous genomic and proteomic analysis
CN112243463B (zh) * 2018-04-09 2024-12-13 小利兰·斯坦福大学托管委员会 原位基因测序方法
KR20220100589A (ko) * 2019-10-18 2022-07-15 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 임상 및 산업 규모의 온전한 조직 시퀀싱
EP4107285B1 (en) * 2020-02-21 2024-10-09 10X Genomics, Inc. Methods and compositions for integrated in situ spatial assay
US12060603B2 (en) * 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
CN114854838A (zh) * 2021-02-04 2022-08-05 美天施生物科技有限两合公司 结合靶向RNA或cDNA体外测序与原位测序的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119068988A (zh) * 2024-08-13 2024-12-03 北京国浩宇医疗科技有限公司 一种针对单细胞表达谱的智能化异常检测系统

Also Published As

Publication number Publication date
AU2022281407A1 (en) 2023-11-30
US20240376530A1 (en) 2024-11-14
EP4644569A3 (en) 2026-01-07
JP2024522350A (ja) 2024-06-18
EP4347878A1 (en) 2024-04-10
CA3219339A1 (en) 2022-12-01
WO2022251586A1 (en) 2022-12-01
KR20240014486A (ko) 2024-02-01
IL308570A (en) 2024-01-01
EP4644569A2 (en) 2025-11-05
EP4347878B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
EP4347878B1 (en) Co-mapping transcriptional states and protein histology
Hwang et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment
Jessa et al. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas
Chumduri et al. Opposing Wnt signals regulate cervical squamocolumnar homeostasis and emergence of metaplasia
Phan et al. A myelin-related transcriptomic profile is shared by Pitt–Hopkins syndrome models and human autism spectrum disorder
Adua et al. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
Huang et al. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
Sherman‐Baust et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high‐grade serous carcinoma development
Fukumura et al. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis
EP4363614B1 (en) Single-cell profiling of rna translation status
Bigler et al. Messenger RNAs localized to distal projections of human stem cell derived neurons
Tauziède‐Espariat et al. NTRK‐rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class
Ning et al. The PAX2‐null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium
WO2017077499A1 (en) Biomarkers of squamous cell carcinoma of head and neck, prognostic markers of recurrence in squamous cell carcinoma of head and neck, and methods thereof
Miele et al. DNA methylation profiling for diagnosing undifferentiated sarcoma with capicua transcriptional receptor (CIC) alterations
Bai et al. Gene expression profiling identifies two chordoma subtypes associated with distinct molecular mechanisms and clinical outcomes
CN117497059B (zh) 一种基于单细胞空间转录图谱的肺腺癌预后分子筛选方法
Sepporta et al. TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth
Griffin et al. Postmortem brain donations vs premortem surgical resections for glioblastoma research: viewing the matter as a whole
Wang et al. Prostaglandin E2-driven dedifferentiation of Schwann cells leads to perineural invasion in pancreatic ductal adenocarcinoma
Gim et al. Spatial transcriptomics shows a distinctive tumour microenvironment in the invasive versus premalignant portion of early cutaneous squamous cell carcinoma
Duan et al. Enrichment of oligodendrocyte precursor phenotypes in subsets of low-grade glioneuronal tumours
Deng et al. Triple-negative breast cancer
Li et al. TGF-β and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma
Li et al. Regulation of cortical neurogenesis by MED13L via transcriptional priming and its implications for MED13L syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination